Literature DB >> 20452758

Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge.

Maciej Kupczyk1, Zofia Kurmanowska, Izabela Kupryś-Lipińska, Małgorzata Bocheńska-Marciniak, Piotr Kuna.   

Abstract

The pathogenetic mechanisms underlying development of persistent inflammation in aspirin (ASA) intolerance are not fully understood. The aim of this study was to determine levels of MCP-3, RANTES, eotaxin, Il-5 and Il-3 in aspirin intolerant asthmatics (AIA) after nasal lysine-aspirin (Lys-ASA) challenge. Twenty AIA and 10 aspirin tolerant controls (ATC) were challenged with saline or 14.4mg of Lys-ASA. Lys-ASA challenge induced clinical symptoms and influx of eosinophils and basophils only in AIA group. Statistically significant higher levels of MCP-3 and RANTES were found in lavages from AIA as compared with ATC (p<0.05 in all time points). Before challenge the average level of MCP-3 was 86.95pg/ml in AIA and 47.61pg/ml in ATC, RANTES levels were 34.20pg/ml in AIA and 17.21pg/ml in ATC and did not change after the challenge in both group. The mean eotaxin's level was 11.01pg/ml in AIA and 8.03pg/ml in ATC before and increased to 20.06, 26.22pg/ml (4 and 24h in AIA) as compared to 10.51, 14.76pg/ml (4 and 24h in ATC) after the challenge (p<0.05). Interleukin-3 and Il-5 were not detectable. The highest inhibition of eosinophils' chemotaxis was induced by anti-eotaxin (47% of inhibition), followed by anti-RANTES (29%), anti-MCP-3 (19%) and anti-Il-5 (9%). In summary, we found that persistent inflammation in AIA patients is characterized by overproduction of MCP-3 and RANTES. Lack of increase in MCP-3 and RANTES levels after Lys-ASA challenge suggest that those mediators are involved in chronic rather than acute phase of ASA induced inflammation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20452758     DOI: 10.1016/j.rmed.2010.04.017

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  12 in total

1.  Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.

Authors:  Jacqueline J Eastman; Kellen J Cavagnero; Adam S Deconde; Alex S Kim; Maya R Karta; David H Broide; Bruce L Zuraw; Andrew A White; Sandra C Christiansen; Taylor A Doherty
Journal:  J Allergy Clin Immunol       Date:  2017-03-06       Impact factor: 10.793

2.  Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Katherine N Cahill; Howard R Katz; Katherine C Murphy; Chunli Feng; Kathleen Lee-Sarwar; Juying Lai; Neil Bhattacharyya; Elliot Israel; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2015-12-12       Impact factor: 10.793

Review 3.  Platelets in patients with aspirin-exacerbated respiratory disease.

Authors:  Tanya M Laidlaw; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2015-06       Impact factor: 10.793

Review 4.  NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets.

Authors:  Tanya M Laidlaw; Joshua M Levy
Journal:  Curr Allergy Asthma Rep       Date:  2020-03-14       Impact factor: 4.806

5.  Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.

Authors:  Katherine N Cahill; Jillian C Bensko; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2014-09-11       Impact factor: 10.793

6.  Role of CCL7 in Type I Hypersensitivity Reactions in Murine Experimental Allergic Conjunctivitis.

Authors:  Chuan-Hui Kuo; Andrea M Collins; Douglas R Boettner; YanFen Yang; Santa J Ono
Journal:  J Immunol       Date:  2016-12-12       Impact factor: 5.422

Review 7.  Aspirin-intolerant asthma: a comprehensive review of biomarkers and pathophysiology.

Authors:  Juan R Velazquez; Luis M Teran
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

8.  Pathogenic Mechanisms and In Vitro Diagnosis of AERD.

Authors:  Dirk Schäfer; Steffen Maune
Journal:  J Allergy (Cairo)       Date:  2012-05-10

9.  A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease.

Authors:  Tanya M Laidlaw; Katherine N Cahill; Juan Carlos Cardet; Katherine Murphy; Jing Cui; Brittney Dioneda; Parul Kothari; Benjamin A Raby; Elliot Israel; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2018-06-08       Impact factor: 10.793

Review 10.  Potential Biomarkers for NSAID-Exacerbated Respiratory Disease.

Authors:  Hanki Park; Youngwoo Choi; Chang-Gyu Jung; Hae-Sim Park
Journal:  Mediators Inflamm       Date:  2017-08-09       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.